Browsing Tag
Zepbound
39 posts
Lilly (NYSE: LLY) now gets 65% of H1 revenue from Mounjaro and Zepbound
Mounjaro and Zepbound generated $27.69 billion for Eli Lilly and Company in H1 2026, or almost 65% of total revenue. Excluding the two tirzepatide brands, revenue grew by only about 11%.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth
ResMed’s FY27 guidance reset pressured RMD despite strong cash flow. Read how Astral, GLP-1 drugs, MatrixCare and buybacks shape the medtech story.
ResMed (ASX: RMD) drops 8% as Astral recall clouds FY27 outlook
ResMed fell 8% as FY27 sales guidance missed expectations. Astral recall costs and slower growth now test the ASX: RMD valuation.
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Eli Lilly’s oral GLP-1 Foundayo gains new women’s health angle with menopause weight-loss data
Lilly’s oral GLP-1 now targets menopause-linked weight gain. Read why Foundayo could sharpen the next obesity drug battleground.